Amarin scores a big win for its cardio outcomes study on Vascepa — stock races higher as analysts applaud
Amarin $AMRN has staked its claim to the next big blockbuster in the cardio space, heralding a clear statistical win on the primary endpoint for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
